---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-061110"
form_type: "8-K"
ticker: "RGNX"
cik: "0001590877"
company_name: "REGENXBIO Inc."
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T09:32:00.961356+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# REGENXBIO cuts 15% workforce, focuses on three lead gene therapies; Q3 net loss $61.9M

## Summary
- Workforce reduction of ~15%, expected $100M cost savings over two years; cash runway extended into H2 2025.
- Q3 revenue $28.9M (Zolgensma royalties $28.4M), net loss $61.9M ($1.41/share) vs $75.5M loss year ago.
- Lead programs: ABBV-RGX-314 (wet AMD/DR), RGX-202 (Duchenne), RGX-121 (MPS II); strategic alternatives for others.
- ABBV-RGX-314 suprachoroidal data: 89% risk reduction in vision-threatening events at one year for dose level 2.
- Cash $364.5M as of Sep 30, 2023, down from $565.2M at Dec 31, 2022.

## SEC filing metadata
- accession: 0000950170-23-061110
- form_type: 8-K
- ticker: RGNX
- cik: 0001590877
- company_name: REGENXBIO Inc.
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590877/000095017023061110/0000950170-23-061110-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590877/000095017023061110/rgnx-20231108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-061110
- JSON: https://secwatch.observer/filing/0000950170-23-061110.json
- Plain text: https://secwatch.observer/filing/0000950170-23-061110.txt

## Key facts
- Earnings Releases
  REGENXBIO Inc. reported financial results for third quarter ended September 30, 2023.
  - Period: third quarter ended September 30, 2023
  - Result: reported results
  source text: REGENXBIO Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590877/000095017023061110/0000950170-23-061110-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.